Inclusion criteria
-
Adults who underwent TKA > 6 months before study entry -
Chronic painful TKA for > 3 months with pain ≥ 6 on a 10-point numerical pain rating scale -
Failed treatments including oral pain medications and were not surgical candidates -
Negative investigation for an infectious etiology by the referring orthopedic surgeon with one or more of the following — normal inflammatory markers, including normal erythrocyte sedimentation rate, or C-reactive protein; normal clinical examination; and/or culture-negative joint fluid aspirate
|
Exclusion criteria
-
History of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or other known diseases of the neuromuscular junction or motor neuron disease -
Concomitant use of aminoglycoside or agents that interfere with neuromuscular junction transmission -
Women who were pregnant or breast-feeding -
Known allergy or sensitivity to the study medication -
Recent or ongoing alcohol or drug abuse -
Known, uncontrolled systemic disease -
Concurrent participation in other drug study
|